Joseph Catanzaro
Stock Analyst at Mizuho
(3.50)
# 928
Out of 5,124 analysts
102
Total ratings
42.35%
Success rate
8.27%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $18.16 | +114.76% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $27.15 | +87.85% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $16.83 | +6.95% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $32.76 | +61.78% | 1 | Dec 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $81 → $120 | $77.81 | +54.22% | 2 | Dec 11, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $24 → $30 | $18.97 | +58.14% | 4 | Dec 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $79.65 | +12.99% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $27.16 | +76.73% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $75.48 | +39.11% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $1.98 | +152.53% | 5 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2.5 → $5 | $4.26 | +17.37% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $2.73 | +119.78% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $17.88 | +151.68% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $122.74 | -10.38% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $43.83 | -13.30% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $20.36 | -26.33% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $67.30 | -21.25% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.81 | +255.87% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.24 | +1,432.26% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.50 | +80.95% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.43 | +517.28% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $16.00 | +125.00% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $9.32 | +329.18% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.14 | +23.61% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.47 | +206.12% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.41 | +1,144.81% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.20 | +1,566.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $8.86 | +103.16% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.60 | +861.54% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.84 | -70.03% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.34 | -14.31% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.82 | -46.81% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $10.67 | +1,774.41% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.36 | +208.10% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.49 | +3,926.85% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.39 | +653.14% | 3 | Apr 7, 2020 |
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $18.16
Upside: +114.76%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $27.15
Upside: +87.85%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $16.83
Upside: +6.95%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $32.76
Upside: +61.78%
Kymera Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $77.81
Upside: +54.22%
Nurix Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $24 → $30
Current: $18.97
Upside: +58.14%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $79.65
Upside: +12.99%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $27.16
Upside: +76.73%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $75.48
Upside: +39.11%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $1.98
Upside: +152.53%
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $4.26
Upside: +17.37%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.73
Upside: +119.78%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $17.88
Upside: +151.68%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $122.74
Upside: -10.38%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $43.83
Upside: -13.30%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $20.36
Upside: -26.33%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $67.30
Upside: -21.25%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.81
Upside: +255.87%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.24
Upside: +1,432.26%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.50
Upside: +80.95%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.43
Upside: +517.28%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $16.00
Upside: +125.00%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $9.32
Upside: +329.18%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.14
Upside: +23.61%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.47
Upside: +206.12%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.41
Upside: +1,144.81%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $8.86
Upside: +103.16%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.60
Upside: +861.54%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.84
Upside: -70.03%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.34
Upside: -14.31%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.82
Upside: -46.81%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $10.67
Upside: +1,774.41%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $11.36
Upside: +208.10%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.49
Upside: +3,926.85%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.39
Upside: +653.14%